Important aspects of carbohydrate metabolism disorders development in hematology/oncology patients during therapy with glucocorticosteroids: a review of the literature
https://doi.org/10.17650/1818-8346-2024-19-2-118-131
Abstract
Glucocorticosteroids are highly effective anti-inflammatory and immunosuppressive agents. The drugs were introduced into therapeutic practice from the mid-20th century and are still widely used in the treatment of various diseases. They are an integral part of the treatment of patients with hematological malignancies. One of the clinically significant complications of glucocorticosteroid therapy is steroid-induced carbohydrate metabolism disorders. Diabetes mellitus is one of the main risk factors for the development of cardiovascular diseases, which are the main non-oncological cause of death in the population and a significant treatment complication in patients with malignant neoplasms. Early detection of the disease and improved treatment efficiency increase the survival rate of patients with various types of neoplasms. It is also important to pay attention to quality of life improving in cancer patients after treatment.
The aim of this review is to analyze the pathogenesis features, as well as predictors of early detection and prevention of possible complications of persistent hyperglycemia in patients with hematological malignancies.
About the Authors
N. T. Vatutin
Donetsk State Medical University named after M. Gorky, Ministry of Health of Russia; V.K. Gusak Institute of Emergency and Reconstructive Surgery, Ministry of Health of Russia
Russian Federation
Russian Federation
16 Prospekt Ilyicha, Donetsk 283003, Donetsk People’s Republic; 47 Prospekt Leninskiy, Donetsk 283045, Donetsk People’s Republic
E. V. Sklyannaya
Donetsk State Medical University named after M. Gorky, Ministry of Health of Russia; V.K. Gusak Institute of Emergency and Reconstructive Surgery, Ministry of Health of Russia
Russian Federation
Russian Federation
16 Prospekt Ilyicha, Donetsk 283003, Donetsk People’s Republic; 47 Prospekt Leninskiy, Donetsk 283045, Donetsk People’s Republic
V. V. Gribov
Donetsk State Medical University named after M. Gorky, Ministry of Health of Russia; City Hospital No. 2 of Makeevka
Russian Federation
Russian Federation
Vadim V. Gribov.
16 Prospekt Ilyicha, Donetsk 283003, Donetsk People’s Republic; 12 Ferganskaya St., Makeevka 286120, Donetsk People’s Republic
References
1. Malignant tumors in Russia in 2020 (morbidity and mortality). Eds.: А.D. Kaprin, V.V. Starinskiy, A.O. Shakhzadova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMITS radiologii” Minzdrava Rossii, 2021. 252 p. (In Russ.).
2. Healy S.J., Nagaraja H.N., Alwan D., Dungan K.M. Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies. Endocrine 2017;56(1):90–7. DOI: 10.1007/s12020-016-1220-2
3. Harris D., Barts A., Connors J. et al. Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study. Curr Oncol 2013;20(6):e532–8. DOI: 10.3747/co.20.1499
4. Hwangbo Y., Kang D., Kang M. et al. Incidence of diabetes after cancer development: a Korean national cohort study. JAMA Oncol 2018;4(8):1099–105. DOI: 10.1001/jamaoncol.2018.1684
5. Toyoshima M.T.K., Cukier P., Souza A.B.C. et al. Effects of glucocorticoids on interstitial glucose concentrations in individuals with hematologic cancer and without known diagnosis of diabetes: a pilot study. Einstein (Sao Paulo) 2022;20:eAO8031. DOI: 10.31744/einstein_journal/2022AO8031
6. Hiestand A., Flory J., Chitkara R. Hospitalization as an opportunity to optimize glycemic control in oncology patients. Curr Diab Rep 2019;19(12):149. DOI: 10.1007/s11892-019-1283-6
7. Wu L., Jiao Y., Li Y. et al. Hepatic Gadd45β promotes hyperglycemia and glucose intolerance through DNA demethylation of PGC-1α. J Exp Med 2021;218(5):e20201475. DOI: 10.1084/jem.20201475
8. Dehghani M., Hobbi A.M., Haghighat S. et al. Glucocorticoid induced diabetes and lipid profiles disorders amongst lymphoid malignancy survivors. Diabetes Metab Syndr 2020;14(6):1645–9. DOI: 10.1016/j.dsx.2020.08.027
9. Chang K.H., Hwang W.L., Muo C.H. et al. Outcome and late effects among acute myeloid leukemia survivors: a nationwide population-based study. Support Care Cancer 2016;24(12): 4993–5000. DOI: 10.1007/s00520-016-3361-5
10. Vidler J., Rogers C., Yallop D. et al. Outpatient management of steroid-induced hyperglycaemia and steroid-induced diabetes in people with lymphoproliferative disorders treated with intermittent high dose steroids. J Clin Transl Endocrinol 2017;9: 18–20. DOI: 10.1016/j.jcte.2017.06.003
11. Ochola L.A., Nyamu D.G., Guantai E.M., Weru I.W. Metformin’s effectiveness in preventing prednisone-induced hyperglycemia in hematological cancers. J Oncol Pharm Pract 2020;26(4):823–34. DOI: 10.1177/1078155219873048
12. Selimov A.Yu., Eliseeva L.N., Kurinnaya V.P., Oranskii S.P. Glucose exchange disorders in patients taking glucocorticosteroids: features of clinical manifestations and correction. Kubanskiy nauchnyy meditsinskiy vestnik = Kuban Scientific Medical Bulletin 2019;26(1):209–18. (In Russ.). DOI: 10.25207/1608-6228-2019-26-1-209-218
13. Agudo-Tabuenca A., Gimeno-Orna J.A., Sáenz-Abad D. Assessment of the efficacy and safety of a protocol to manage glucocorticoid-induced hyperglycemia in diabetic patients during hospital stay. Endocrinol Diabetes Nutr 2019;66(6):353–60. DOI: 10.1016/j.endinu.2019.01.008
14. Wallace M.D., Metzger N.L. Optimizing the treatment of steroid-induced hyperglycemia. Annal Pharmacother 2018;52(1):86–90. DOI: 10.1177/1060028017728297
15. Vu K., Busaidy N., Cabanillas M.E. et al. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2012;12(5):355–62. DOI: 10.1016/j.clml.2012.05.004
16. Beaupere C., Liboz A., Fève B. et al. Molecular mechanisms of glucocorticoid-induced insulin resistance. Int J Mol Sci 2021;22(2):623. DOI: 10.3390/ijms22020623
17. Welsch S., Sawadogo K., Brichard B. et al. Characterization and risk factors of hyperglycaemia during treatment of childhood hematologic malignancies. Diabet Med 2022;39(2):e14720. DOI: 10.1111/dme.14720
18. Suh S., Park M.K. Glucocorticoid-induced diabetes mellitus: an important but overlooked problem. Endocrinol Metab 2017;32(2):180–9. DOI: 10.3803/EnM.2017.32.2.180
19. Bonaventura A., Montecucco F. Steroid-induced hyperglycemia: an underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract 2018;139:203–20. DOI: 10.1016/j.diabres.2018.03.006
20. Gebauer J., Fick E.M., Waldmann A. et al. Self-reported endocrine late effects in adults treated for brain tumours, Hodgkin and non-Hodgkin lymphoma: a registry based study in Northern Germany. Eur J Endocrnol 2015;173(2):139–48. DOI: 10.1530/eje-15-0174
21. Hirabayashi K., Nakazawa Y., Matsuura H. et al. Risk factors for diabetes mellitus and impaired glucose tolerance following allogeneic hematopoietic stem cell transplantation in pediatric patients with hematological malignancies. Int J Hematol 2014;99(4):477–86. DOI: 10.1007/s12185-014-1536-8
22. Li C., Liu P., Liu L. et al. Metabolic syndrome in hematologic malignancies survivors: a meta-analysis. Med Oncol 2015;32(1):422. DOI: 10.1007/s12032-014-0422-9
23. Šimkovič M., Vodárek P., Motyčková M. et al. Rituximab, cyclophosphamide and dexamethasone (RCD) chemoimmunotherapy for relapsed chronic lymphocytic leukaemia. Eur J Clin Invest 2020;51(4):e13421. DOI: 10.1111/eci.13421
24. Ceccarelli E., Mattaliano C., Brazzi A. et al. Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients: revision of literature and personal considerations. Curr Pharm Biotechnol 2018;19(15):1210–20. DOI: 10.2174/1389201020666190102145305
25. Cavataio M.M., Packer C.D. Steroid-induced diabetic ketoacidosis: a case report and review of the literature. Cureus 2022;14(4):e24372. DOI: 10.7759/cureus.24372
26. Jung S.H., Jang H.C., Lee S.S. et al. The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma. Biomed Res Int 2014;2014:413149. DOI: 10.1155/2014/413149
27. Weiser M.A., Cabanillas M.E., Konopleva M. et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer 2004;100(6):1179–85. DOI: 10.1002/cncr.20071
28. Gonzalez-Gonzalez J.G., Mireles-Zavala L.G., Rodriguez-Gutierrez R. et al. Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients. Diabetol Metab Syndr 2013;5:18. DOI: 10.1186/1758-5996-5-18
29. Lee S.Y., Kurita N., Yokoyama Y. et al. Glucocorticoid-induced diabetes mellitus in patients with lymphoma treated with CHOP chemotherapy. Support Care Cancer 2014;22(5):1385–90. DOI: 10.1007/s00520-013-2097-8
30. Bostrom B.C., Sensel M.R., Sather H.N. et al. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood 2003;101(10):3809–17. DOI: 10.1182/blood-2002-08-2454
31. Teuffel O., Kuster S.P., Hunger S.P. et al. Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis. Leukemia 2011;25(8):1232–8. DOI: 10.1038/leu.2011.84
32. Bielorai B., Pinhas-Hamiel O. Type 2 diabetes mellitus, the metabolic syndrome, and its components in adult survivors of acute lymphoblastic leukemia and hematopoietic stem cell transplantations. Curr Diab Rep 2018;18(6):32. DOI: 10.1007/s11892-018-0998-0
33. Lamar Z.S., Dothard A., Kennedy L. et al. Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration – a retrospective study. Leuk Lymphoma 2018;59(8):1871–7. DOI: 10.1080/10428194.2017.1410889
34. Pagano G., Cavallo-Perin P., Cassader M. et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin resistance in healthy subjects. J Clin Invest 1983;72(5): 1814–20. DOI: 10.1172/JCI111141
35. Weinstein S.P., Wilson C.M., Pritsker A., Cushman S.W. Dexamethasone inhibits insulin-stimulated recruitment of GLUT4 to the cell surface in rat skeletal muscle. Metabolism 1998;47(1): 3–6. DOI: 10.1016/s0026-0495(98)90184-6
36. Seckl J.R., Morton N.M., Chapman K.E., Walker B.R. Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue. Recent Prog Horm Res 2004;59:359–93. DOI: 10.1210/rp.59.1.359
37. Linssen M.M., van Raalte D.H., Toonen E.J. et al. Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells. Cell Signal 2011;23(11):1708–15. DOI: 10.1016/j.cellsig.2011.06.002
38. Esguerra J.L.S., Ofori J.K., Nagao M. et al. Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA. Mol Metab 2020;32:160–7. DOI: 10.1016/j.molmet.2019.12.012
39. Roberts A., James J., Dhatariya K. Management of hyperglycaemia and steroid (glucocorticoid) therapy: a guideline from the Joint British Diabetes Societies (JBDS) for Inpatient Care group. Diabetic Med 2018;35(8):1011–7. DOI: 10.1111/dme.13675
40. Dev R., Bruera E., Dalal S. Insulin resistance and body composition in cancer patients. Ann Oncol 2018;29(suppl_2):ii18–26. DOI: 10.1093/annonc/mdx815
41. Tanaka K., Okada Y., Mori H. et al. The effects of mitiglinide and repaglinide on postprandial hyperglycemia in patients undergoing methylprednisolone pulse therapy. Intern Med 2018;57(1):65–70. DOI: 10.2169/internalmedicine.9013-17
42. Boren J., Cascante M., Marin S. et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem 2001;276(41):37747–53. DOI: 10.1074/jbc.M105796200
43. Clore J.N., Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr Pract 2009;15(5):469–74. DOI: 10.4158/EP08331.RAR
44. Perez A., Jansen-Chaparro S., Saigi I. et al. Glucocorticoid-induced hyperglycemia. J Diabetes 2014;6(1):9–20. DOI: 10.1111/1753-0407.12090
45. Zarkovic M., Beleslin B., Ciric J. et al. Glucocorticoid effect on insulin sensitivity: a time frame. J Endocrinol Invest 2008;31(3):238–42. DOI: 10.1007/BF03345596
46. Gounden V., Ngu M., Anastasopoulou C., Jialal I. Fructosamine. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2022.
47. Olczuk D., Priefer R. A history of continuous glucose monitors (CGMs) in self-monitoring of diabetes mellitus. Diabetes Metab Syndr 2018;12(2):181–7. DOI: 10.1016/j.dsx.2017.09.005
48. Fonseca V.A., Grunberger G., Anhalt H. et al. Continuous glucose monitoring: a consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract 2016;22(8):1008–21. DOI: 10.4158/EP161392.CS
49. Seelig E., Meyer S., Timper K. et al. Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol 2017;176(3):349–58. DOI: 10.1530/EJE-16-0653
50. Willi S.M., Kennedy A., Brant B.P. et al. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract 2002;58(2):87–96. DOI: 10.1016/s0168-8227(02)00127-4
51. Wu W., Merriman K., Nabaah A. et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 2014;111(3):628–36. DOI: 10.1038/bjc.2014.307
52. De Micheli A. [Corticosteroid induced diabetes mellitus: diagnosis and management] (In Italian). G Ital Nefrol 2016;33(S68):gin/33.S68.7.
53. Ali N.A., O’Brien J.M.Jr, Blum W. et al. Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality. Cancer 2007;110(1):96–102. DOI: 10.1002/cncr.22777
54. Kuvshinov A.Yu., Voloshin S.V., Kuzyaeva A.A. et al. Current views on CAR-Т therapy. Vestnik gematologii = Bulletin of Hematology 2019;15(2):4–13. (In Russ.).
Review
For citations:
Vatutin N.T., Sklyannaya E.V., Gribov V.V. Important aspects of carbohydrate metabolism disorders development in hematology/oncology patients during therapy with glucocorticosteroids: a review of the literature. Oncohematology. 2024;19(2):118-131. (In Russ.) https://doi.org/10.17650/1818-8346-2024-19-2-118-131
Views:
1469
Email this article 